Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 4/20 | 0.37 |
| ▸ | ECE1 | P42892 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | ITGAL | P20701 | 1/20 | 0.34 |
| ▸ | GNPAT | O15228 | 1/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30798035 | 0.95 | MME (0.41) | MMEECE1GNPATENPEP | |
| SCHEMBL29373629 | 0.94 | ECE1 (0.39) | MMEBACE1ECE1MEN1KMT2A | |
| SCHEMBL30192164 | 0.93 | BACE1 (0.36) | MMEBACE1ECE1ITGB2ICAM1 | |
| SCHEMBL30477911 | 0.93 | MME (0.39) | MMEECE1GNPATENPEPOPRD1 | |
| SCHEMBL29360643 | 0.93 | MME (0.42) | MMEECE1GNPATENPEP | |
| SCHEMBL31596910 | 0.92 | BACE1 (0.47) | BACE1OPRD1 | |
| SCHEMBL29510840 | 0.92 | MME (0.38) | MMEBACE1GNPATENPEP | |
| SCHEMBL30859432 | 0.92 | MME (0.40) | MMEECE1GNPATENPEP | |
| SCHEMBL30973091 | 0.91 | BACE1 (0.43) | BACE1ENPEPOPRD1 | |
| SCHEMBL29913867 | 0.91 | ECE1 (0.36) | MMEBACE1ECE1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583922-B2 | Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof | NOVIMMUNE SA (CH) | 2026-03-24 | — | — | US | claimed |
| US-12448444-B2 | Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof | NOVIMMUNE SA (CH) | 2025-10-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583922-B2 | Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof | CD47, PDCD1LG2, CD274 | MME 4248/4885BACE1 2025/4885ECE1 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.